New Hampshire Trust Decreases Position in Pfizer Inc. (NYSE:PFE)

New Hampshire Trust reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.4% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 18,333 shares of the biopharmaceutical company’s stock after selling 1,247 shares during the period. New Hampshire Trust’s holdings in Pfizer were worth $465,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock worth $13,756,738,000 after buying an additional 2,285,276 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC lifted its stake in Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock worth $3,190,131,000 after purchasing an additional 2,923,537 shares in the last quarter. Norges Bank purchased a new position in Pfizer in the 4th quarter worth approximately $2,328,986,000. Finally, Massachusetts Financial Services Co. MA lifted its stake in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE PFE opened at $23.46 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm’s 50 day moving average is $23.12 and its 200-day moving average is $25.07. The company has a market capitalization of $133.38 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.82 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.33%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Analysts Set New Price Targets

PFE has been the topic of a number of research reports. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.